Pathology Assessment of Renal Masses
Keywords:
PATHOLOGY, KIDNEY NEOPLASMS, NEPHRECTOMY, LAPAROSCOPY.Abstract
Introduction: renal masses are a biologically heterogeneous group of tumors that can be benign or malignant. Renal carcinomas represent 85% of solid tumors.
Objective: to describe the anatomo-pathological results of renal masses in patients operated by laparoscopic surgery and identify the possible relation among the histological subtypes and other variables.
Methods: an observational, analytic, cohort retrospective study that included 120 patients who underwent laparoscopic radical and partial nephrectomies, of those patients diagnosed with renal masses and treated from 2015-2020 was carried out. Descriptive statistics was utilized, and Student’s t-test and Ji-Square test (p>0,05) were used to correlate variables.
Results: average age 58,2 years, males prevailed (65,8 %), incidental diagnosis (64,2 %), ASA II (45,8 %) and the R.E.N.A.L score was low/moderate. 85 % of the masses were malignant, in stage pT1a (53,9 %), significantly most were operated by radical nephrectomy (p=0,03). Cancer-specific survival was 98,8 % and mean follow-up time, 26,62 months (±1,97). The older age of the patients was associated to malignant tumors (p=0,0). Survival and tumor size were not related to histological subtypes (p>0,05, respectively).
Conclusions: malignant renal masses prevailed and among them clear cell carcinoma, which was associated to older age. The malignant histological subtype and clear cell carcinoma were associated to the older age of the patients. Tumor size and survival were not associated to histological subtypes.
Downloads
References
1. Kutikov A, Fossett LK, Ramchandani P, et al. Incidence of benign pathologic findings at partial nephrectomy for solitary renal mass presumed to be renal cell carcinoma on preoperative imaging. Urology [Internet]. 2006 [Citado 15/01/2024]; 68(4): 737–740. Disponible en: https://doi.org/10.1016/j.urology.2006.04.011
2. Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol [Internet]. 2019 [Citado 16/01/2024]; 30(5):706-20. Disponible en: https://doi.org/10.1093/annonc/mdz056.
3. World Health Organization (WHO). Global Health Estimates 2020: Deaths by Cause, Age, Sex, by Country and by Region, 2000–2019 [Internet]. WHO: Geneva, Switzerland; 2020. [Citado 15/01/2024]. Disponible en: https://knowledge-action-portal.com/en/news_and_events/video-archive/6409
4. González Valdés M. Anuario Estadístico de Salud de Cuba. Rev Méd Electrón [Internet]. 2016 [citado 13/02/2024]; 38(5): 792-796. Disponible en: https://revmedicaelectronica.sld.cu/index.php/rme/article/view/1720
5. Makino T, Kadomoto S, Izumi K, Mizokami A. Epidemiology and Prevention of Renal Cell Carcinoma. Cancers [Internet]. 2022 [Citado 15/01/2024]; 14(16): 4059. Disponible en: https://doi.org/10.3390/cancers14164059
6. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol [Internet]. 2016 [Citado 11/02/2020]; 70(1): 93-105. Disponible en: https://pubmed.ncbi.nlm.nih.gov/26935559/
7. González León T, Albelo Abreu Y, Sánchez Tamaki R, Morera Pérez M, Quintana Rodríguez M, Álvarez Herrera S. Resultados oncológicos de la nefrectomía radical laparoscópica. Rev Cub Urol [Internet]. 2020 [Citado 02/01/2020]; 9(3): 116-127. Disponible en: http://www.revurologia.sld.cu/index.php/rcu/article/view/623/679
8. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA [Internet]. 2013 Nov 27 [Citado 02/01/2020]; 310(20): 2191-4. Disponible en: https://pubmed.ncbi.nlm.nih.gov/24141714/
9. Salgia NJ, Philip EJ, Ziari M, Yap K, Pal SK. Advancing the Science and Management of Renal Cell Carcinoma: Bridging the Divide between Academic and Community Practices. J Clin Med [Internet]. 2020 [Citado 09/10/2020]; 9(5): 1508. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290777/
10. Vasudev NS, Wilson M, Stewart GD, Adeyoju A, Cartledge J, Kimuli M, et al. Challenges of early renal cancer detection: symptom patterns and incidental diagnosis rate in a multicentre prospective UK cohort of patients presenting with suspected renal cancer. BMJ Open [Internet]. 2020 [cited 08/10/2020]; 10(5): e035938. Available from: https://pubmed.ncbi.nlm.nih.gov/32398335
11. Tomita Y, Kondo T, Kimura G, Inoue T, Wakumoto Y, Yao M, et al. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up. Jpn J Clin Oncol [Internet]. 2020 [Citado 10/10/2020]; 50(1): 12-9. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31633185/
12. Ochoa GL, Zuleta JJ, Valencia C, Martínez C, Correa JJ. Sistema de puntaje para nefrometría RENAL score interobservador. Urol Colomb [Internet]. 2016 [Citado 08/10/2020]; 25(2): 75-80. Disponible en: https://www.clinicalkey.es/service/content/pdf/watermarked/1-s2.0-S0120789X15001252.pdf?locale=es_ES&searchIndex=
13. Wang Y, Ding Y, Wang J, Gu M, Wang Z, Qin C, et al. Clinical features and survival analysis of clear cell papillary renal cell carcinoma: A 10-year retrospective study from two institutions. Oncol Lett [Internet]. 2018 [Citado 13/10/2020]; 16(1): 1010-22. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29963177/
14. Mitchell TJ, Turajlic S, Rowan A, Nicol D, Farmery JHR, O'Brien T, et al. Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal. Cell [Internet]. 2018 [Citado 13/04/2020]; 173(3): 611-23.e17. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927631/
15. Verdecia Vázquez J, Quintana Rodríguez M, Garay Cruz SB, González León T. Tumor renal mucinoso. Rev Cub Urol [Internet]. 2020 [Citado 02/01/2021]; 9(2): 68-73. Disponible en: http://www.revurologia.sld.cu/index.php/rcu/article/view/577/661
16. Wang L, Hughes I, Snarskis C, Alvarez H, Feng J, Gupta GN, et al. Tumor enucleation specimens of small renal tumors more frequently have a positive surgical margin than partial nephrectomy specimens, but this is not associated with local tumor recurrence. Virchows Arch [Internet]. 2017 [Citado 15/10/2021]; 470(1): 55-61. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27778094/
17. Pierorazio PM, Johnson MH, Patel HD, Sozio SM, Sharma R, Iyoha E, et al. Management of Renal Masses and Localized Renal Cancer: Systematic Review and Meta-Analysis. J Urol [Internet]. 2016 [Citado 10/10/2020]; 196(4): 989-99. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27157369/
18. Oake JD, Patel P, Lavallée LT, Lattouf J-B, Saarela O, Klotz L, et al. Outcomes and prognosticators of stage 4 renal cell carcinoma with pathological T4 primary lesion using a large, Canadian, multi-institutional database. Can Urol Assoc J [Internet]. 2020 [Citado 8/10/2020]; 14(2): 24-30. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012283/
19. Nandanan N, Veccia A, Antonelli A, Derweesh I, Mottrie A, Minervini A, et al. Outcomes and predictors of benign histology in patients undergoing robotic partial or radical nephrectomy for renal masses: a multicenter study. Cent European J Urol [Internet]. 2020 [Citado 15/10/2020]; 73(1): 33-8. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203778/
20. Nguyen DP, Vertosick EA, Corradi RB, Vilaseca A, Benfante NE, Touijer KA, et al. Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy. Urol Oncol [Internet]. 2016 [Citado 8/10/2020]; 34(6): 259.e1-.e259. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133368/.
Downloads
Published
How to Cite
Issue
Section
License
Authors who have publications with this journal agree to the following terms: Authors will retain their copyrights and grant the journal the right of first publication of their work, which will be publication of their work, which will be simultaneously subject to the Creative Commons Attribution License (CC-BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g.: deposit it in an institutional telematic archive or publish it in a volume). Likewise, and according to the recommendations of the Medical Sciences Editorial (ECIMED), authors must declare in each article their contribution according to the CRediT taxonomy (contributor roles). This taxonomy includes 14 roles, which can be used to represent the tasks typically performed by contributors in scientific academic production. It should be consulted in monograph) whenever initial publication in this journal is indicated. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which may produce interesting exchanges and increase citations of the published work. (See The effect of open access). https://casrai.org/credit/
